印尼婴儿第4次访视时同时接种一剂二价口服脊灰疫苗与DTwP-Hb-Hib及灭活脊灰疫苗的免疫原性和安全性
研究纳入143名满足入选标准的新生儿,出生时接种首剂二价口服脊灰疫苗(bOPV),第60、90、120天与DTwP-Hb-Hib(Pentabio®)同时接种bOPV,第120天加种一剂灭活脊灰疫苗(IPV)。第4剂bOPV后P1、P2、P3血清保护率分别为100%、91.6%、99.3%,血清阳转率分别为100.0%、93.3%、100%,无严重不良事件,全身反应总体轻微。
要点
- 第4剂bOPV后P1、P2、P3血清保护率分别为100%、91.6%、99.3%。
- 第4剂bOPV后P1、P2、P3血清阳转率分别为100.0%、93.3%、100%。
- 无严重不良事件,接种后1–28天全身反应总体轻微。
核心结论
- bOPV与Pentabio®及一剂IPV在第4次访视时同时接种具有免疫原性且耐受性良好。
研究设计与样本
- 研究纳入143名满足入选标准的新生儿并完成研究,出生时接种首剂bOPV,第60、90、120天与Pentabio®同时接种bOPV,第120天加种一剂IPV。
- 在第0天(首剂bOPV前)、第60天(第2剂bOPV前)及末剂bOPV后30天采集血清进行血清学分析,并评估不良事件的强度、持续时间及与试验疫苗的关系。
主要发现
- 第4剂bOPV后脊髓灰质炎病毒P1、P2、P3血清保护率分别为100%、91.6%、99.3%。
- 第4剂bOPV后脊髓灰质炎病毒P1、P2、P3血清阳转率分别为100.0%、93.3%、100%。
- 无严重不良事件,接种后1–28天全身反应总体轻微。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In this study, we aimed to evaluate the immunological protectivity of infants following four doses of bivalent oral polio vaccine (bOPV; Bio Farma), which were given simultaneously with DTwP-Hb-Hib (Pentabio®), along with one dose of inactivated poliovirus vaccine (IPV) at the fourth visit. A total of 143 newborn infants who fulfilled the inclusion criteria were enrolled and completed the study. Subjects received the first dose of bOPV at birth. On days 60, 90 and 120, bOPV was given simultaneously with Pentabio®. On day 120, one dose of IPV was also administered. Serum samples for serology analysis were collected before the first dose of bOPV (at day 0), before the second dose of bOPV (at day 60) and 30 days after the last dose of bOPV. In addition, the intensity, duration and relationship of each adverse event to the trial vaccines were assessed. Seroprotection rates after the fourth dose of bOPV were 100%, 91.6% and 99.3% for poliovirus P1, P2 and P3, respectively. Seroconversion rates after the fourth dose of bOPV were 100.0%, 93.3% and 100% for poliovirus P1, P2 and P3, respectively. There were no severe adverse events, and systemic reactions were generally mild during the 1-28 day post-vaccination period. Collectively, our findings indicate that bOPV given simultaneously with Pentabio® and one dose of IPV at the 4th visit was immunogenic and well tolerated.
引用
- Fadlyana E, Dhamayanti M, Tarigan R, et al. Immunogenicity and safety profile of a primary dose of bivalent oral polio vaccine given simultaneously with DTwP-Hb-Hib and inactivated poliovirus vaccine at the 4th visit in Indonesian infants. Vaccine. 2020. PMID: 31982261. doi:10.1016/j.vaccine.2020.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。